Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Fallet

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Lung Cancer (Amsterdam, Netherlands)|September 26, 2022
Characterization of lung cancers in patients with BRCA germline variants: A multicenter seriesMateo Sanchis-Borja, Vincent Fallet, Elisabeth Fabre, et al.
Respiratory Medicine and Research|January 3, 2026
Increased delays of care during the COVID-19 pandemic: experience of a lung cancer rapid diagnostic centerPascal Wang, Anthony Canellas, Floriane Millet, et al.
Translational Lung Cancer Research|July 11, 2026
End-of-life management and causes of death in ALK-positive non-small cell lung cancer in France: a multicentric analysisGaspard Naulleau, Gary Birsen, Pascal Wang, et al.
Oncotarget|April 19, 2017
MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lungRaphaël Saffroy, Vincent Fallet, Nicolas Girard, et al.
The Lancet. Respiratory Medicine|July 11, 2020
Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort studyCharles-Hugo Marquette, Jacques Boutros, Jonathan Benzaquen, et al.
Lung Cancer (Amsterdam, Netherlands)|July 6, 2014
Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lungThibault Vieira, Martine Antoine, Anne-Marie Ruppert, et al.
ERJ Open Research|April 26, 2018
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancerAdrien Costantini, Jennifer Corny, Vincent Fallet, et al.
Pharmaceutics|September 23, 2022
Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung CancerThomas Rodier, Alicja Puszkiel, Evelina Cardoso, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2018
c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid CarcinomasXavier Mignard, Anne-Marie Ruppert, Martine Antoine, et al.
JTO Clinical and Research Reports|January 24, 2025
Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLCFrancesca Lucibello, Valérie Gounant, Mihaela Aldea, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Lung Cancer (Amsterdam, Netherlands)|September 26, 2022
Characterization of lung cancers in patients with BRCA germline variants: A multicenter seriesMateo Sanchis-Borja, Vincent Fallet, Elisabeth Fabre, et al.
Respiratory Medicine and Research|January 3, 2026
Increased delays of care during the COVID-19 pandemic: experience of a lung cancer rapid diagnostic centerPascal Wang, Anthony Canellas, Floriane Millet, et al.
Translational Lung Cancer Research|July 11, 2026
End-of-life management and causes of death in ALK-positive non-small cell lung cancer in France: a multicentric analysisGaspard Naulleau, Gary Birsen, Pascal Wang, et al.
Oncotarget|April 19, 2017
MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lungRaphaël Saffroy, Vincent Fallet, Nicolas Girard, et al.
The Lancet. Respiratory Medicine|July 11, 2020
Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort studyCharles-Hugo Marquette, Jacques Boutros, Jonathan Benzaquen, et al.
Lung Cancer (Amsterdam, Netherlands)|July 6, 2014
Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lungThibault Vieira, Martine Antoine, Anne-Marie Ruppert, et al.
ERJ Open Research|April 26, 2018
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancerAdrien Costantini, Jennifer Corny, Vincent Fallet, et al.
Pharmaceutics|September 23, 2022
Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung CancerThomas Rodier, Alicja Puszkiel, Evelina Cardoso, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2018
c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid CarcinomasXavier Mignard, Anne-Marie Ruppert, Martine Antoine, et al.
JTO Clinical and Research Reports|January 24, 2025
Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLCFrancesca Lucibello, Valérie Gounant, Mihaela Aldea, et al.
Pageof 6